Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NFKBIB
REST API REST API
Homo sapiens
NFKBIB is differentially expressed in 257 experiments: 117 organism parts: testis, dorsal root ganglion, ... (115 more);, 193 disease states: normal, glioblastoma, ... (191 more);, 70 cell types 361 cell lines 43 compound treatments and 75 other conditions.
Synonyms IKBB, TRIP9
Orthologs Q0IIB2_BOVIN (Bos taurus)   Nfkbib (Rattus norvegicus)   Nfkbib (Mus musculus)   NFKBIB (Danio rerio)   cact (Drosophila melanogaster)   Q4H3C2_CIOIN (Ciona intestinalis)   NFKBIB (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Toll signaling pathway, cytosol, protein binding, cytoplasm, innate immune response, transcription, DNA-dependent, signal transducer activity, transcription coactivator activity, nucleus, positive regulation of NF-kappaB transcription factor activity, signal transduction, toll-like receptor 4 signaling pathway, toll-like receptor signaling pathway, toll-like receptor 3 signaling pathway, toll-like receptor 2 signaling pathway, MyD88-dependent toll-like receptor signaling pathway, cytoplasmic sequestering of NF-kappaB, MyD88-independent toll-like receptor signaling pathway, toll-like receptor 1 signaling pathway
InterPro Term Ankyrin_rpt, Ankyrin_rpt-contain_dom
UniProt Accession Q15653, Q59EM7
Search EB-eye ENSG00000104825
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (27 experiments)

Factor Value U/D Experiments
Jurkat
2
E-GEOD-1880, E-MEXP-2197
SNU1
2
E-MTAB-37, E-GEOD-15460
MOLT4
2
E-MTAB-37, E-MTAB-62
BT474
2
E-MTAB-62, E-MTAB-37
T47D
2
E-MTAB-62, E-MEXP-440
NCIH747
1
E-MTAB-37
355 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, E-GEOD-13987, ... (40 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
fibroblast
2
E-GEOD-3920, E-GEOD-26672
mononuclear
2
E-GEOD-13987, E-GEOD-26672
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18147, E-GEOD-18265
liver cancer
1
E-GEOD-21154
adipocyte
1
E-AFMX-5
64 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-2069, E-GEOD-1577, E-GEOD-22148, ... (48 experiments)

Factor Value U/D Experiments
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
adenocarcinoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
lymphoma
2
E-MTAB-62, E-MTAB-37
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
187 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (26 experiments)

Factor Value U/D Experiments
none
3
6
E-MEXP-1601, E-GEOD-5824, E-TABM-868, E-MEXP-1958, E-GEOD-412, ... (9 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
BCR/FGFR1
1
E-GEOD-15811
mercury dichloride
1
E-GEOD-6907
propofol
1
E-GEOD-4386
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-MEXP-2340

Genotype
studied in E-TABM-763, E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-GEOD-2292, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-3606, E-GEOD-20876, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-MEXP-1403

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-TABM-43, ... (7 experiments)

Tumor size
studied in E-GEOD-4922

Processing time: 0.276 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM